会议日程 - 2016年美国精细化工展览会

活动首页网站首页

ON-SITE EDUCATION

The 2016 Conference Program will serve to foster dialogue on innovation and commercialization trends, regulatory challenges, market dynamics and opportunities for growth within today’s rapidly growing chemical markets including, the broader energy field, pharmaceuticals, life sciences and agrochemicals. Educational sessions will also highlight opportunities in new innovative sub segments such as green chemistry, 3-D printing and electronic chemicals.

Wednesday, February 3, 2016

8:30 AM - 9:30 AM

Opening Remarks: Best Practices for Successful Outsourcing Partnerships
Lawrence Sloan, President/CEO of SOCMA

SOCMA CEO and President, Larry Sloan, will open the 2016 meeting by discussing the latest trends in custom contract manufacturing. His opening remarks will look at the drivers that impact a successful partnership and pitfalls to avoid, making sure to take into account the perspectives from both the supplier and customer.

Opening Keynote: Chemistry in Cuba: Opportunities for Strategic Partnerships in the Wake of Open US-Cuba Relations

Luis Alberto Montero-Cabrera, Professor at the University of Havana, President of the Cuban Chemical Society

With US and Cuban relations now beginning to thaw, the opportunities for business development and collaboration could be endless. Hear from Professor Luis Alberto Montero-Cabrera, President of the Cuban Chemical Society and Professor of Chemistry at the University of Havana, as he discusses their more notorious and available scientific achievements in the fields of biotechnology, medicinal chemistry and nanotechnology and how companies and research institutions from the US and abroad could work with Cuba's scientific community to drive innovation and commercial partnerships between and for the good of both countries.

Time	Blue Theater	Orange Theater
10:00 - 10:30 AM	Crop Protection's Innovative Future Gary Johansson, North American Manufacturing Technology Manager, DuPont John Anderson, Economic Evaluator, Dow Agrosciences John Caudill, Owner, Contract Manufacturing Strategies, LLC In this session, representatives from DuPont, Dow AgroSciences, and CAC will discuss how the crop protection industry is using innovation to create new opportunities, which serve to address recent regulatory scrutiny and herbicide resistance challenges. The innovations that will be discussed include the development of molecules with increased specificity and lower use rates among others.	Life Science Industry Outlook Panel Moderator: Theral Timpson, Host and Producer, Mendelspod The host of the popular science podcast Mendelspod will bring together the leaders responsible for driving success across the life sciences to discuss industry trends and opportunities for growth across the drug development continuum in the coming year.
10:45 - 11:15 AM	Green Solvents – Replacing Dirty & Toxic with Clean & Green David Pasin, President , TBF Environmental Technology, Inc. The purpose of this paper is to review new MIR & VOC regulations in various jurisdictions within the United States and how the use of green solvents will help manufacturers meet them. It also looks at what constitutes a Green Solvent, the differences between what are classed as Green Solvents, their safety and use in a variety of applications which range from formulation, surface preparation and cleaning. The paper will examine the short and long-term effects of the new regulations, the effect of typical solvents on the health of the worker and the environment and how green solvents solve many issues for manufacturers. The use of Green Solvents will also the company to reduce it regulatory burdens, improve regulatory compliance, improve its public relations and sales and improve productivity through reducing workplace exposure and injuries related to exposure to toxic solvents.	How Preformulation and Formulation Development Can Optimize API Properties for Better Drug Design Elanor Pinto, Ph.D, Technical Project Manager, Catalent Micron Technologies The success of a new chemical entity (NCE) relies on the preformulation screening of lead candidates and robust and efficacious formulation development based on the compound’s physicochemical and biopharmaceutical properties. Early stage prediction of these properties is beneficial in selection of suitable technologies in optimizing the bioavailability, safety, and stability of the NCE candidate. Intuitive design of suitable formulation for clinical studies streamline pharmacokinetic and efficacy/toxicity studies leading to pharmacologically effective and developable candidates to reach the clinic and eventually the market faster. Working with reliable and well-established partners with the expertise in preformulation and formulation development results in substantial cost savings and expedites successful development of candidates from clinical to market.
11:30 AM - 12:00 PM	Exploring the Economic Impact of Electronic Materials on the Mobile Device Industry Simon McElre, CEO, Semblant Electronic materials have more often than not been associated with manufacturing processes and their ability to solve technical challenges or enhance performance. Now, a new line of electronic materials is emerging to help better protect devices from costly returns and repairs due to mechanical and liquid damage. This session will explore the various ways in which innovative chemistry will change the mobile device industry. By adding protective coatings to devices, manufacturers can protect devices from the inside adding value to the electronics supply chain in new and unforeseen ways. The session will also look the environmental considerations for new materials and avoiding the use of harmful substances such as PFOA, PFOA-derivatives and C6 - chemicals known to cause harm that are being systematically banned by companies such as Apple, Nike and Patagonia.	Safety and Security of the Pharmaceutical Supply Chain – What Suppliers Need to Know Now Moderator: Scott Watson, Principal, The C=C Bond Group Increasing regulatory and inspection requirements, along with multiple threats to the pharmaceutical supply chain, mean that suppliers are under more scrutiny than ever. This hard-hitting panel will discuss recent changes in regulatory and inspection requirements and offer suppliers practical measures to take now. The panelists will include senior quality leaders from pharma, biotech, suppliers, and these with real world experience at the regulatory agencies. We all know that quality is non-negotiable when making materials, which will go into medicines. In this panel you will gain insights, which will help your company stay in compliance and avoid costly errors. This panel will benefit senior business leaders and owners, quality professionals, operations leaders and business development professionals who want the most current information applicable to supplier to the pharmaceutical supply chain.
12:00 - 2:00 PM	Lunch Available
2:00 - 2:30 PM	Synthetic Biology: Ushering in a New Era of Chemical Engineering Development and De-Risking Devin Leake, Vice President of R&D and Operations , Gen9 Noah Helman, Co-Founder and CSO, Industrial Microbes	A New Dimension: How 3D Tissue Models Can Help to Advance Compound Development and De-Risking Randy Strube, Director of Global Marketing, InSphero Cell-based assays have become an inherent part of drug discovery and development to predict the in vivo response to chemicals, serving as a test system for target validation, primary and secondary screening, lead optimization and toxicological profiling. Advanced 3D tissue models provide a format, which reflects in vivo cellular functionality, either animal or human, as closely as possible, and gain momentum as a time and cost-saving means to improve drug de-risking. Engineering strategies for producing 3D models of various complexity and scalability will be discussed along with their exploitation to further improve the predictive power of in vitro assays.
2:45 - 3:15 PM	Lessons Learned: Successfully Commercializing Advanced Biotechnologies Mark Warner Founder, Warner Advisors Significant time and resources have been spent within industrial biotechnology to commercialize innovative fuels and chemicals. Much of this progression began with early stage biofuels (ethanol and biodiesel), moved to advanced biofuels (cellulosic and algae) and has evolved into broad chemical applications. Each of these categories has seen success with facilities being built and becoming operational, while other ventures struggle to put “steel in the ground”. This presentation will review projects over the last 10 years and focus on the factors that allowed certain ventures to move successfully from concept to commercial operation.	Your Company’s Best Discovery? R&D Tax Credits Yair Holtzman Partner and Chemicals & Energy Practice Group Leader, Anchin, Block & Anchin LLP Accountants and Advisors
3:30 - 4:00 PM	Chipping in: Opportunities for Growth in the Specialty Chemicals Industry Aida Jebens, Principal Analyst, IHS In an environment of intense competition, increased government regulations, and industry structural changes, specialty chemicals manufacturers must continue to innovate in order to stay relevant. Innovation is a “must” whether you are serving the exacting demands of the automotive industry or the fickle needs of the consumer market. This session will provide an overview of the largest end-use markets and regions for specialty chemicals and outline the key trends driving growth. Then it will take a deeper exploration into semiconductor manufacturing, where innovation in chemicals enables the industry to adhere to Moore’s Law. The presentation will highlight some of the major manufacturing trends and show where chemicals play a critical role. It will discuss the major chemicals used in each of the major manufacturing steps, provide current and projected market size, and discuss the key chemical suppliers. Finally, it will outline several critical requirements of how to become a successful chemical supplier to this industry.	Creating an Ecosystem of Open Innovation to Foster External Collaboration in the Pharmaceutical Industry Dr. Chandra , Ramanathan Senior Director, Innovation Strategy & Global Lead, External Innovation, Bayer Innovation is critical for pharmaceutical companies to bring successful products to address unmet patient needs. Now more than ever, pharmaceutical companies are looking to external partners to inspire innovation, even at the earliest stages of drug development. At Bayer, the goal is to secure sustainable access to future innovation through flexible partnering strategies. The company’s collaboration approach plays an integral role in driving customer value, while simultaneously fostering an innovation ecosystem in an ever-changing industry environment. This presentation will look beyond traditional collaboration models and provide insight into how open innovation sourcing can be used to create highly-networked organizations, which leverage internal crowdsourcing to enhance engagement strategies with partners and customers alike.

Thursday, February 4, 2016

8:30 - 9:30 AM

Closing Keynote: Incorporating Green Chemistry into Commercially Relevant Applications Today
John Warner, President and Chief Technology Officer, Warner Babcock Institute, LLC

The use of green chemistry across a range of industries continues to grow rapidly, offering companies an expected direct and indirect cost savings of $65.5 billion by 2020, according to Pike Research. To help companies reap the benefits of this significant trend, InformEx 2016 closing keynote features John Warner, seminal founder of green chemistry, and the co-founder, president and chief technology officer of the Warner Babcock Institute of Green Chemistry. Known for his 12 Principles of Green Chemistry, John is the foremost authority on how green chemistry can be immediately incorporated into commercially relevant applications. InformEx attendees will learn how to improve composition and profitability of their products and production processes.

Time	Blue Theater	Orange Theater
10:00 - 10:30 AM	Industrial BioBusiness Novvi	What Is Your Company Doing to Respond to the Need for More Sustainable Products BASF
10:45 - 11:15 AM	Conflict Mineral Disclosure: Insight into Development International’s 2014 SEC Filing Evaluation Michael McCoy, Lead Analyst, Development International Similar to Conflict or Blood Diamonds, Conflict Minerals refers to raw materials that come from a particular part of the world where conflict is occurring and affects the mining and trading of those materials. To address the use of Conflict Minerals, President Obama signed the Dodd-Frank Consumer Protection Act into law in 2010. Dodd-Frank Section 1502 requires public companies to reveal the origin of the so-called “conflict minerals” – tin, tungsten, tantalum, and gold – contained in their products. Development International (DI) evaluated 1,271 public companies’ SEC “conflict mineral” filings for reporting year 2014 to offer an independent perspective on filers’ conformance with the SEC Rule. The evaluation’s principal instrument features compliance criteria, juxtaposed with a “good practice” metric. DI’s presentation will provide an overview of the act, describe the two evaluation metrics, highlight disclosure results and issues we observed in our survey, as well as anticipate reporting challenges for next year's disclosure round.	Standardizing Green Chemistry Models The Wercs
11:30 AM - 12:00 PM	Bridging the Gap Between the Industry Leaders of Today and Future Innovators of Tomorrow: An Interactive Panel on Preparing the Next Generation for Commercial Success TBD	How to Maximize the Value of Your Business: An Introduction to Value Based Management, and How it Can Transform Your Business Kevin Ramsier, Managing Partner & CEO, Vesticor Advisors, LLC Understanding what increases the value of your business, and what specific actions need to be taken to recognize that value are critical concepts for any business growth strategy. The most successful businesses in the world manage their operations with a focus on daily activities that increase the value of the business. Nearly 50% of the businesses in our industry will transition ownership over the next decade, and understanding the key elements that drive business valuations will be more important than ever. The concepts in this session are not just for someone thinking about selling their business soon, they are tested business methods that are best practices for any business.
12:00 - 2:00 PM	Lunch Available

联系我们

www.informex.com

Informex Holdings, LLC
2 Penn Plaza
15th Floor
New York, NY 10121
T: +1(415)947-6350
informex@informex.com